Objective-Atherosclerotic plaques with large lipid cores and inflammation contain regions of hypoxia. We examined the uptake of 2-(2-nitro-1 H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl) acetamide ([ 18 F]EF5), a specific marker of hypoxia labeled for positron emission tomography, in mouse atherosclerotic plaques.
A therosclerosis is a chronic inflammatory disease of artery wall. The majority of myocardial infarctions result from sudden ruptures of atherosclerotic plaques. Atherosclerotic plaques that are vulnerable to rupture are characterized by extensive inflammation, neoangiogenesis, a thin fibrous cap, and a large lipid core. Circulating monocytes are recruited to plaques, where they differentiate into macrophages. The majority of macrophages transform into foam cells by accumulating lipids in their cytoplasm, thus forming the main component of the plaque lipid core. 1, 2 At this stage, plaques with a large necrotic core contain severely hypoxic areas. 3 Hypoxia constitutes an important signal for plaque growth by inducing formation of lipid droplets in macrophages, increasing the secretion of inflammatory mediators, and increasing intraplaque angiogenesis. 2, 4, 5 Therefore, we hypothesized that, if present, plaque hypoxia could offer a new biomarker of plaque growth and vulnerability.
2-(2-Nitro-1 H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl) acetamide ([ 18 F]EF5) is a novel and specific 6 positron emission tomography tracer approved by the US Food and Drug Administration for in vivo detection of hypoxia. 7-10 EF5 has been used to detect hypoxia in rodent and human tumors, 8, 11, 12 and it has shown good correlation with other hypoxia markers, such as hypoxia-inducible transcription factor 1. 5, 13 EF5 undergoes a biochemical reduction by nitroreductases in viable cells and forms covalent adducts to intracellular macromolecules in the absence of oxygen. 14 Therefore, only viable hypoxic cells are detectable with EF5. EF5 is a lipophilic compound and has better pharmacokinetic properties than other nitroimidazole compounds. 15 Recently, [ 18 F]EF5 positron emission tomography imaging has been introduced as a promising tool for the detection of hypoxia in tumor tissues in patients 7 and in experimental models. 8, 9 In the present study, we aimed at investigating whether atherosclerotic plaques contain hypoxic regions as detected with [ 18 F]EF5 in atherosclerotic mouse models. In addition to [ 18 F]EF5 accumulation, we examined the detection of EF5 adducts by using the specific Cy-3-conjugated monoclonal antibody ELK3-51, and additionally, hypoxia was confirmed by using pimonidazole. We also compared the [ 18 F]EF5 uptake with the plaque histology and macrophage content.
Materials and Methods
A detailed description of the Materials and Methods is provided in the Supplemental Material, available online at http://atvb.ahajournals.org.
Animals
Atherosclerotic mice deficient for low-density lipoprotein receptor and synthesizing only apolipoprotein B100 (LDLR Ϫ/Ϫ ApoB 100/100 ), as well as LDLR Ϫ/Ϫ ApoB 100/100 mice overexpressing insulinlike growth factor II (IGF-II) in pancreatic ␤ cells 16 (IGF-II/LDLR Ϫ/Ϫ ApoB 100/100 ) to induce diabetes, were fed a high-cholesterol Western-type diet (0.2% total cholesterol, TD 88137, Harlan Teklad) for 3 to 4 months, starting at the age of 4 to 8 months. Two different models were used to induce plaques with variable phenotypes. The IGF-II/LDLR Ϫ/Ϫ ApoB 100/100 mice exhibited insulin resistance and hyperglycemia (type 2 diabetes), as well as hypercholesterolemia (from the LDLR Ϫ/Ϫ ApoB 100/100 background) associated with a rapid development of atherosclerotic plaques. It was used in the present study as a model of the most inflamed types of atherosclerotic plaques. 16 A subset of wild-type C57BL/6N mice received a regular chow diet and served as nonatherosclerotic controls. The experiments were approved by the local animal committee and carried out in compliance with the Finnish laws relating to the conduct of animal experimentation.
Synthesis of [ 18 F]EF5
[ 18 F]EF5 was synthesized from 2-(2-nitro-1 H-imidazol-1-yl)-N-(2,3,3-trifluoroallyl)-acetamide, as described previously. 7
Ex Vivo Biodistribution Studies
The biodistribution of intravenously administered [ 18 F]EF5 at 90 minutes after injection was studied in 6 LDLR Ϫ/Ϫ ApoB 100/100 , 6 IGF-II/LDLR Ϫ/Ϫ ApoB 100/100 , and 6 C57BL/6N mice. The 90minute accumulation time was based on the serum half-life of EF5 in mice (T 1 ⁄2ϭ40 minutes). 17 Because the biological half-life of EF5 is relatively long, 4 additional LDLR Ϫ/Ϫ ApoB 100/100 mice were studied at 180 minutes postinjection to explore the biodistribution of [ 18 F]EF5 in more detail. The mice were anesthetized with isoflurane, injected with [ 18 F]EF5 (11Ϯ2 MBq) via a tail vein, and euthanized 90 or 180 minutes after injection. The basic characteristics of the animals are shown in Table 1 . The ascending aorta to the level of diaphragm was dissected, and blood was rinsed with saline. The radioactivity in aorta, blood, fat, heart, kidney, liver, and muscle was measured using a gamma counter. The radioactivity concentration was expressed as a percentage of the injected activity per gram of tissue (%IA/g). In addition, a total of 12 atherosclerotic hearts (from 7 LDLR Ϫ/Ϫ ApoB 100/100 and 5 IGF-II/LDLR Ϫ/Ϫ ApoB 100/100 mice) were collected and preserved in formalin for further study.
Autoradiography
An autoradiography (ARG) analysis was performed to study the distribution of [ 18 F]EF5 in the aortic tissue. Briefly, the aorta was frozen and cut in sequential longitudinal 8-and 20-m cryosections. The sections were apposed to an imaging plate, and after an exposure time of 4 hours, the imaging plates were scanned (Fuji Analyzer BAS 5000). After coregistration of the autoradiographs and images of hematoxylin/eosin-stained 20-m sections, 18 F radioactivities were measured in the following regions of interest: (1) plaque (excluding media), (2) adventitia (including adjacent fat), and (3) normal vessel wall (media remote from atherosclerotic lesions) and given as photostimulated luminescence units per mm 2 . The background was subtracted from the image data, and the results from each mouse were normalized for injected activity and decay. An example of the ARG analysis is shown in Supplemental Figure I . As previously reported, the measurements by 2 independent observers are reproducible (coefficient of variation 4.5%). 18
Histology
Following the ARG analysis, macrophages were identified on adjacent 8-m sections using a rat anti-mouse Mac-3 antibody (BD Pharmingen, clone M3/84). The plaques were visually graded as noninflamed (none or occasional Mac-3 positive macrophages) or inflamed (groups of macrophages or abundant infiltration of macrophages) 19 and compared with the corresponding [ 18 F]EF5 uptake. To characterize atherosclerosis in more detail, formalin-fixed and paraffin-embedded hearts with the aortic root were transversely cut into 5-m sections at the level of the coronary ostia, followed by staining with anti-mouse Mac-3 antibody and modified Movat pentachrome staining. The intima-to-media ratio was determined from the Movat-stained section, and the Mac-3 positive area of each plaque was calculated using the automated image analysis software (Image-Pro Plus 5.0, Media Cybernetics).
Verification of Plaque Hypoxia
Plaque hypoxia was verified through the detection of EF5 adducts, after injection of nonlabeled EF5 (kindly provided by C.J. Koch), using a specific monoclonal antibody ELK3-51 conjugated to the fluorescent dye Cy-3 in 4 additional (2 LDLR Ϫ/Ϫ ApoB 100/100 and 2 IGF-II/LDLR Ϫ/Ϫ ApoB 100/100 ) mice. Furthermore, plaque hypoxia was confirmed by the staining of tissue sections after injection of pimonidazole in 2 additional (1 LDLR Ϫ/Ϫ ApoB 100/100 and 1 IGF-II/LDLR Ϫ/Ϫ ApoB 100/100 ) mice, using a fluorescein isothiocyanateconjugated anti-pimonidazole antibody.
Statistics
All results are expressed as meanϮSD. Nonpaired data comparisons between 2 groups were made using the t test, and comparisons between multiple groups were made using ANOVA with the Tukey correction. The paired t test was used for comparing paired data between 2 groups. All analyses were performed with SAS (version 9.1, SAS Institute, Inc., Cary, NC). Values of PϽ0.05 were considered statistically significant.
Results

Characterization of Atherosclerosis
The aortas of the C57BL/6N control mice showed no atherosclerosis. The atherosclerotic LDLR Ϫ/Ϫ ApoB 100/100 mice developed atherosclerotic plaques covering large areas of aorta and also in the abdominal aorta. Atherosclerotic plaques were also seen in IGF-II/LDLR Ϫ/Ϫ ApoB 100/100 mice, but they were less extensive than in LDLR Ϫ/Ϫ ApoB 100/100 mice. Representative Mac-3-and Movat-stained aortic root sections are shown in Figure 1 . In all mice, the plaques were mostly of the fibroatheroma type with a well-defined fibrous cap ( Figure  1 ). The plaques of LDLR Ϫ/Ϫ ApoB 100/100 mice were larger and had typically larger necrotic cores than the fibrosis-rich plaques seen in IGF-II/LDLR Ϫ/Ϫ ApoB 100/100 mice. Consistent with this, the intima-to-media ratio in the aortic root was significantly larger in LDLR Ϫ/Ϫ ApoB 100/100 mice (3.6Ϯ1.3) than IGF-II/LDLR Ϫ/Ϫ ApoB 100/100 mice (0.9Ϯ0.2, PϽ0.001). The atherosclerotic plaques in both LDLR Ϫ/Ϫ ApoB 100/100 and IGF-II/LDLR Ϫ/Ϫ ApoB 100/100 mice were highly inflamed. The extent of Mac-3 positive areas in the plaques from the 
Biodistribution of [ 18 F]EF5
The results of the [ 18 F]EF5 biodistribution analysis are shown in 
[ 18 F]EF5 Uptake in Atherosclerotic Plaques
The ARG analysis revealed significantly higher [ 18 F]EF5 uptakes in the plaques than in the normal vessel wall in all the atherosclerotic mice. In total, 1505 regions of interest (523 in plaques, 555 in normal vessel wall, and 427 in adventitia) were analyzed from 16 atherosclerotic and 6 control mice. At 90 minutes after injection, the plaque-to-normal vessel wall ratio was 2.2Ϯ0.2 (Pϭ0.0001 plaque versus wall) in LDLR Ϫ/Ϫ ApoB 100/100 mice and 1.9Ϯ0.2 (Pϭ0.0004 plaque versus wall) in IGF-II/LDLR Ϫ/Ϫ ApoB 100/100 mice. At 180 minutes after injection, the plaque-to-normal vessel wall ratio was 1.9Ϯ0.2 (Pϭ0.01 plaque versus wall) in LDLR Ϫ/Ϫ ApoB 100/100 mice. Importantly, [ 18 F]EF5 uptake in the normal vessel wall was similar between the atherosclerotic strains and control mice ( Table 3 ). The uptake of [ 18 F]EF5 in plaques did not show clear predilection sites, and there were no differences between calcified and noncalcified regions. In addition to plaques, the adventitia immediately adjacent to aorta showed [ 18 F]EF5 uptake in both atherosclerotic mouse strains and controls. The average plaque-to-adventitia ratio was 1.0Ϯ0.2 (nϭ16; not significant) and the normal vessel wall-toadventitia ratio did not differ significantly between athero- 
[ 18 F]EF5 Uptake and Plaque Inflammation
The degree of inflammation in the plaques was semiquantitatively assessed from randomly selected plaque regions of interest by observing the density of Mac-3 positive cells. A total of 21 noninflamed and 127 inflamed plaques were analyzed in both mouse strains, either 90 or 180 minutes after injection (pooled data of plaque-to-normal vessel wall ratio, 1.1Ϯ0.4, nϭ16; not significant).
Verification of Plaque Hypoxia
The presence of hypoxia-specific EF5 adducts in the deep layers of plaques was confirmed by fluorescent microscopy using Cy-3-conjugated ELK3-51 antibody after the injection of nonlabeled EF5 in both atherosclerotic models. The adventitia and wall areas were not stained with ELK3-51 antibody. A positive signal was also seen in plaques by fluorescent microscopy after injection of pimonidazole and subsequent staining with anti-pimonidazole antibody in both atherosclerotic models. Figure 2 shows the EF5 adducts and pimonidazole visualized with green fluorescence. Hypoxia immunoreactivity was not detected in the plaques of the mice not injected with EF5 and pimonidazole.
Discussion
In this article, we report for the first time that hypoxia in atherosclerotic plaques of atherosclerotic mice can be detected with [ 18 F]EF5 by using ex vivo methods. The uptake of [ 18 F]EF5 was higher in the aortas of atherosclerotic LDLR Ϫ/Ϫ ApoB 100/100 mice with large plaques than in C57BL/6N control mice. ARG showed consistent, focally increased uptake of [ 18 F]EF5 in atherosclerotic plaques, as compared with normal vessel wall of the same animals. The uptake of [ 18 F]EF5 appeared to be unrelated to the degree of plaque inflammation confirmed by anti-Mac-3 antibody immunohistochemical staining. The blood concentrations of [ 18 F]EF5 remained quite high, potentially limiting the feasibility of [ 18 F]EF5 for noninvasive imaging of atherosclerotic plaques with [ 18 F]EF5 in this model. Hypoxic areas have been detected in advanced human atherosclerotic lesions and in rabbit models of atherosclerosis. 3, 4, 20 Until recently, it has been controversial whether mouse atherosclerotic plaques are hypoxic. The threshold for hypoxia depends on the oxygen diffusion distance, which is governed by plaque thickness. In mice, the plaque thickness is usually smaller than the depth at which severe hypoxia is detected in rabbit and human plaques (100 to 250 m). However, it was recently shown that the plaques in the carotid artery in LDLR Ϫ/Ϫ mice are more hypoxic (4.4 to 55.2% of plaque hypoxia) compared with the plaques in the carotid arteries of symptomatic patients (0.4 to 23.5%) as detected by pimonidazole. 10 In a tumor model, the 2 hypoxia markers, namely pimonidazole and EF5, were found to colocalize. 21 In the present study, we verified hypoxia in LDLR Ϫ/Ϫ ApoB 100/100 and IGF-II/LDLR Ϫ/Ϫ ApoB 100/100 mouse aortic plaques by means of injecting EF5 adduct specific antibody and pimonidazole.
In this study, the ex vivo biodistribution results demonstrated a significantly higher aorta uptake of [ 18 F]EF5 in those LDLR Ϫ/Ϫ ApoB 100/100 mice that showed extensive and large atherosclerotic plaques than in the control mice. Our observation that aortic [ 18 F]EF5 uptake of diabetic IGF-II/ LDLR Ϫ/Ϫ ApoB 100/100 mice was comparable to that of control mice is likely explained by the small size of plaques, as verified by the calculation of intima-to-media ratio in the aortic root of IGF-II/LDLR Ϫ/Ϫ ApoB 100/100 mice. Thus, our results suggest that hypoxia is consistently present in advanced and large atherosclerotic plaques in atherosclerotic mice.
ARG showed much higher [ 18 F]EF5 uptake in atherosclerotic plaques than in normal vessel wall in all atherosclerotic mice. However, the slow blood clearance suggests that [ 18 F]EF5 is strongly bound to the plasma proteins, which lengthens its half-life in the circulation. The circulatory half-life of EF5 has been reported to be approximately 40 minutes in mice. 17 Uptake of [ 18 F]EF5 in adventitia observed in this study was nonspecific, probably because of the presence of blood in the adventitial microvessels and tissue processing. This is suggested by a deficiency of EF5 adducts in the immunofluorescence staining. The slow blood clearance and the high adventitial uptake may limit the value of [ 18 F]EF5 for in vivo imaging of atherosclerosis, but this remains to be tested in other models and in humans.
Hypoxia may have an important role in the progression of atherosclerotic lesions by promoting lipid accumulation, inflammation, and angiogenesis. 4 It has been reported earlier that the hypoxia observed in advanced atherosclerotic plaques is directly correlated to the extent of macrophages and neovascularization. 5 Consistent with previous studies, we found that plaques were rich in macrophages (up to 60% of plaque area). In this study, the uptake of [ 18 F]EF5 was at the same level in the inflamed and noninflamed plaques as detected by Mac-3 staining. However, it is important to notice that the content of macrophages in plaques is heterogeneous, and macrophages can express different antigens. 22 Expression of Mac-3 antigen is upregulated during differentiation of monocytes into activated macrophages, which can be detected by anti-Mac-3 antibody immunohistochemical staining in the cap area and in the shoulder regions of the plaques. It has been previously shown that in advanced human carotid atherosclerotic plaques, the cap shows mild or no hypoxia, whereas the shoulder segment of the plaque is not hypoxic, irrespective of the infiltration of macrophages. However, the hypoxia is present in the center of an advanced plaque and colocalizes with CD68-positive macrophages. 5 This may also explain the difference in the [ 18 F]EF5 uptake and Mac-3 positive macrophages in our study.
The ARG analysis of very small structures is challenging, and variation in the results is expected. We compensated for this by analyzing several regions in serial sections, thus adding the effect of multiple measurements. The variability of the ARG method has been previously tested by 2 independent observers, and the coefficient of variation was always Ͻ10%, which is considered acceptable. 18 In conclusion, our study provides evidence that hypoxia in advanced atherosclerotic plaques can be a potential target for identifying high-risk plaques. Our findings encourage pursuing additional studies with hypoxia-specific tracers for detecting high-risk atherosclerotic plaques by noninvasive imaging.
